Understanding diagnostic pathways in systemic sclerosis and systemic sclerosis-associated interstitial lung disease: A retrospective cohort study

被引:3
|
作者
Assassi, Shervin [1 ]
Shao, Nan [2 ]
Yin, Ziwei [2 ]
Volkmann, Elizabeth R. [3 ]
Zoz, Donald F. [2 ]
Leonard, Thomas B. [2 ]
机构
[1] Univ Texas McGovern Med Sch, Div Rheumatol, 6431 Fannin St, Houston, TX 77030 USA
[2] Boehringer Ingelheim Pharmaceut Inc, 90 E Ridge POB 368, Ridgefield, CT 06877 USA
[3] Univ Calif Los Angeles, David Geffen Sch Med, Dept Med, Div Rheumatol, Los Angeles, CA 90095 USA
关键词
administrative claims; delayed diagnosis; healthcare; pulmonary fibrosis; scleroderma; systemic; IDIOPATHIC PULMONARY-FIBROSIS; CLASSIFICATION; MANAGEMENT; CRITERIA; UPDATE; DEATH;
D O I
10.1097/MD.0000000000029993
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Systemic sclerosis-associated interstitial lung disease (SSc-ILD) is usually detected in a patient known to have SSc but may be diagnosed prior to SSc. We probed an insurance database to investigate documentation of ILD prior to SSc. Using Optum's Clinformatics (R) Data Mart Database, we identified patients with an SSc index date between January 1, 2010, and September 30, 2015, based on International Classification of Diseases (ICD)-9-Clinical Modification (CM) codes, >= 2 medical claims associated with SSc on different dates within 1 year, and >= 3 years of continuous enrollment prior to SSc index date (ICD-9-CM cohort). We identified an ICD-10-CM cohort comprising patients with an SSc index date between October 1, 2017, and June 30, 2019, based on ICD-10-CM codes, >= 2 medical claims associated with SSc on different dates within 1 year, and >= 2 years of continuous enrollment prior to SSc index date. ILD was defined as >= 2 medical claims associated with ILD on different dates. The ICD-9-CM and ICD-10-CM cohorts comprised 1779 and 1032 patients, respectively. In these cohorts, respectively, 7.6% and 9.3% of patients had their second medical claim associated with ILD prior to their SSc index date, and 4.3% and 5.6% of patients had their second medical claim associated with ILD >1 year prior to the SSc index date. In this analysis, 4% to 6% of patients with SSc had claims for ILD >1 year prior to a claim for SSc. These data show that SSc can affect the lung early and demonstrate the importance of screening patients with SSc for ILD and patients with ILD for SSc.
引用
收藏
页数:5
相关论文
共 50 条
  • [1] Understanding Diagnostic Pathways in Systemic Sclerosis and Systemic Sclerosis-Associated Interstitial Lung Disease (SSc-ILD)
    Assassi, Shervin
    Shao, Nan
    Yin, Ziwei
    Volkmann, Elizabeth
    Zoz, Donald
    Leonard, Thomas
    ARTHRITIS & RHEUMATOLOGY, 2020, 72
  • [2] A retrospective cohort study of outcome in systemic sclerosis-associated interstitial lung disease
    Okamoto, Masaki
    Fujimoto, Kiminori
    Sadohara, Junko
    Furuya, Kiyomi
    Kaieda, Shinjiro
    Miyamura, Tomoya
    Suematsu, Eiichi
    Kitasato, Yasuhiko
    Kawayama, Tomotaka
    Ida, Hiroaki
    Ichiki, Masao
    Hoshino, Tomoaki
    RESPIRATORY INVESTIGATION, 2016, 54 (06) : 445 - 453
  • [3] Epidemiology of systemic sclerosis and systemic sclerosis-associated interstitial lung disease
    Bergamasco, Aurore
    Hartmann, Nadine
    Wallace, Laura
    Verpillat, Patrice
    CLINICAL EPIDEMIOLOGY, 2019, 11 : 257 - 273
  • [4] Systemic sclerosis-associated interstitial lung disease
    Scallan, Ciaran J.
    Collins, Bridget F.
    Raghu, Ganesh
    CURRENT OPINION IN PULMONARY MEDICINE, 2020, 26 (05) : 487 - 495
  • [5] Systemic sclerosis-associated interstitial lung disease
    Perelas, Apostolos
    Silver, Richard M.
    Arrossi, Andrea, V
    Highland, Kristin B.
    LANCET RESPIRATORY MEDICINE, 2020, 8 (03): : 304 - 320
  • [6] Treatment for systemic sclerosis-associated interstitial lung disease
    Roofeh, David
    Lescoat, Alain
    Khanna, Dinesh
    CURRENT OPINION IN RHEUMATOLOGY, 2021, 33 (03) : 240 - 248
  • [7] Nintedanib for Systemic Sclerosis-Associated Interstitial Lung Disease
    Distler, Oliver
    Highland, Kristin B.
    Gahlemann, Martina
    Azuma, Arata
    Fischer, Aryeh
    Mayes, Maureen D.
    Raghu, Ganesh
    Sauter, Wiebke
    Girard, Mannaig
    Alves, Margarida
    Clerisme-Beaty, Emmanuelle
    Stowasser, Susanne
    Tetzlaff, Kay
    Kuwana, Masataka
    Maher, Toby M.
    NEW ENGLAND JOURNAL OF MEDICINE, 2019, 380 (26): : 2518 - 2528
  • [8] Nintedanib for Systemic Sclerosis-Associated Interstitial Lung Disease
    Moran-Mendoza, Onofre
    Alharthi, Bader
    Clements-Baker, Marie
    NEW ENGLAND JOURNAL OF MEDICINE, 2019, 381 (16): : 1595 - 1595
  • [9] Management of systemic sclerosis-associated interstitial lung disease
    Roofeh, David
    Jaafar, Sara
    Vummidi, Dharshan
    Khanna, Dinesh
    CURRENT OPINION IN RHEUMATOLOGY, 2019, 31 (03) : 241 - 249
  • [10] Treatment of systemic sclerosis-associated interstitial lung disease
    Prasse, A.
    Bonella, F.
    Mueller-Ladner, U.
    Witte, T.
    Hunzelmann, N.
    Distler, J.
    ZEITSCHRIFT FUR RHEUMATOLOGIE, 2020, 79 (03): : 294 - 303